Skip to main content
Two women smiling. One woman looking down.

How can the KISQALI dose be adjusted to help manage adverse reactions?

For patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence, in combination with an aromatase inhibitor (AI), the once-daily KISQALI® (ribociclib) dose can be reduced from 400 mg (2 x 200-mg tablets) orally to one 200-mg tablet, as needed, to help manage adverse reactions. See clinical guidance below for KISQALI dose adjustments in eBC.1
Reference: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.